Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025

Core Insights - Regeneron Pharmaceuticals, Inc. will report its first quarter 2025 financial and operating results on April 29, 2025, before U.S. markets open [1] - A conference call and webcast will be held at 8:30 AM Eastern Time on the same day [1] Company Overview - Regeneron is a leading biotechnology company focused on inventing, developing, and commercializing medicines for serious diseases [3] - The company was founded and is led by physician-scientists, emphasizing a strong connection between scientific research and medical application [3] - Regeneron's product pipeline targets various conditions, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases [3] Technological Advancements - Regeneron utilizes proprietary technologies like VelociSuite to produce optimized fully human antibodies and new classes of bispecific antibodies [4] - The company leverages data-powered insights from the Regeneron Genetics Center and pioneering genetic medicine platforms to identify innovative treatment targets [4]